|
|
Article: CSL Biotherapies Contracts with U.S. Department of Health and Human Services HHS to Provide Novel a H1N1 Influenza Vaccine Antigen.
- Article from:
- Vaccine Weekly
- Article date:
- June 17, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CSL Biotherapies, Inc. announced that it has signed a contract with the U.S. Department of Health and Human Services (HHS) to provide Novel A (H1N1) influenza vaccine antigen in bulk form to support HHS' pandemic influenza preparedness efforts. The initial order under contract will be for an amount of at least $180 million. CSL Biotherapies anticipates initial delivery of the antigen by September, subject to regulatory approval. The new vaccine antigen will be tested in clinical trials funded by HHS (see also CSL Biotherapies, Inc.).
CSL Biotherapies has also negotiated an option to supply HHS with Novel A (H1N1) antigen filling and finishing services at the ...